Rich DiPaolo, Ph.D.

2010-2011
The following is a description of a study from one of the many researchers that our organization has funded.

Treating RA with regulatory T cells

Image
Rich DiPaolo, Ph.D.
St. Louis University
St. Louis, Missouri
John Vaughan Scholar

Adoptively Transferring GPI-specific Regulatory T cells to treat the Effector Phase of Rheumatoid Arthritis

The immune system generates a population of cells known as regulatory T cells. These cells are the immune system’s way of controlling inflammation and preventing the development of various autoimmune diseases. Many scientists are studying regulatory T cells to learn how to use these cells to treat inflammation and autoimmunity. If regulatory T cells are to be of clinical use, they must be able to suppress inflammation when administered during later stages of an ongoing autoimmune disease.

Dr. DiPaolo has discovered that regulatory T cells can be used to reduce the severity of inflammation and joint disease in a mouse model of Rheumatoid Arthritis (RA). In this project, Dr. DiPaolo will determine how effective this treatment is at more advanced stages of disease. In addition he will investigate cellular targets and mechanisms used by regulatory T cells to suppress inflammation in the joints. These studies will provide novel insight into the potential to use regulatory T cells, or drugs that mimic their activity, to treat RA and potentially other autoimmune diseases.

You may return to the list of research that we have funded.
Pin It